Why Nuwellis Stock Is Climbing
Why Nuwellis Stock Is Climbing
"We are thrilled to introduce QUELIMMUNE to critically ill pediatric patients in need. This marks a significant step forward in Nuwellis' mission to execute our pediatric business development strategy. By partnering with SeaStar Medical, we are committed to bringing this groundbreaking therapy to U.S. healthcare providers, offering new hope to children suffering from severe immune system reactions," said Nuwellis, Inc. (NASDAQ:NUWE) shares are trading higher Monday after the company announced Friday that the first pediatric patient has been treated with the newly launched Quelimmune therapy in a commercial setting.
Nuwellis，Inc.（纳斯达克：NUWE）股票周一交易上涨，此前公司宣布，周五第一个儿科患者在商业环境下接受新推出的Quelimmune疗法治疗。
The Details:
细节：
Quelimmune is a novel therapy designed to treat pediatric patients suffering from acute kidney injury (AKI) with sepsis or a septic condition and requiring kidney replacement therapy (KRT) manufactured for SeaStar Medical Holding Corp (NASDAQ:ICU) and exclusively licensed and distributed in U.S. pediatric hospitals by Nuwellis.
Quelimmune是一种新型治疗急性肾损伤（AKI）伴有脓毒症或脓毒症状态并需要肾脏替代治疗（KRT）的小儿患者的疗法，由SeaStar Medical Holding Corp（纳斯达克：ICU）制造，并由Nuwellis在美国小儿医院独家许可和分销。
"We are thrilled to introduce QUELIMMUNE to critically ill pediatric patients in need. This marks a significant step forward in Nuwellis' mission to execute our pediatric business development strategy. By partnering with SeaStar Medical, we are committed to bringing this groundbreaking therapy to U.S. healthcare providers, offering new hope to children suffering from severe immune system reactions," said Nestor Jaramillo, CEO of Nuwellis.
“我们很高兴将QUELIMMUNE介绍给需要的重症小儿患者。这是Nuwellis执行我们的小儿业务发展战略迈出的重要一步。通过与SeaStar Medical合作，我们致力于将这种开创性的疗法带给美国的医疗机构，为患有严重免疫系统反应的儿童提供新的希望，”Nuwellis的CEO Nestor Jaramillo说。
Roth MKM analyst Jonathan Aschoff initiated coverage on Nuwellis with a Buy rating and a $17 price target Monday. According to data from Benzinga Pro, Nuwellis shares are trading below the stock's 50-day moving average of $6.30 and near its 52-week low of $2.19.
Roth MKm的分析师Jonathan Aschoff周一对Nuwellis进行了买入评级，并给出了17美元的目标价。根据Benzinga Pro的数据，Nuwellis的股票价格低于6.30美元的50日移动平均线，接近其52周低点2.19美元。
How To Buy NUWE Stock:
如何购买NUWE股票：
By now you're likely curious about how to participate in the market for Nuwellis – be it to purchase shares, or even attempt to bet against the company.
现在你可能好奇如何参与Nuwellis的市场，无论是购买股票，甚至试图对该公司进行做空。
Buying shares is typically done through a brokerage account. You can find a list of possible trading platforms here. Many will allow you to buy 'fractional shares,' which allows you to own portions of stock without buying an entire share. For example, some stock, like Berkshire Hathaway, or Amazon.com, can cost thousands of dollars to own just one share. However, if you only want to invest a fraction of that, brokerages will allow you to do so.
购买股票通常是通过证券账户进行的。您可以在这里找到可能的交易平台列表。许多交易平台将允许您购买“碎股”，这样可以购买部分股票而非整张股票。例如，有些股票，如伯克希尔-哈撒韦公司或亚马逊公司，可能需要数千美元才能持有一股。但是，如果您只想投资其中一小部分，券商将允许您这样做。
If you're looking to bet against a company, the process is more complex. You'll need access to an options trading platform, or a broker who will allow you to 'go short' a share of stock by lending you the shares to sell. The process of shorting a stock can be found at this resource. Otherwise, if your broker allows you to trade options, you can either buy a put option, or sell a call option at a strike price above where shares are currently trading – either way it allows you to profit off of the share price decline.
如果您想押注股票下跌，流程就更为复杂了。您需要访问期权交易平台，或者找一家券商让您通过借出股票进行“开空”操作（借股出售）。您可以在该资源中了解到卖空股票的过程。否则，如果您的券商允许您交易期权，您可以在当前股票交易价以上的执行价上购买看跌期权或者卖出看涨期权 - 无论哪种情况都可以让您从股票价格下跌中获利。
NUWE Price Action: According to Benzinga Pro, Nuwellis shares are up 20.8% at $2.90 at the time of publication Monday.
NUWE的价格变动：根据Benzinga Pro的数据，在周一发表时，Nuwellis的股票价格上涨了20.8%，报2.90美元。
Read Also:
阅读更多：
- Carbon Revolution Stock Races On Chevrolet Corvette ZR1 Wheels
- 碳革命股票以雪佛兰Corvette ZR1车轮冲刺
Image: Unsplash
图片：Unsplash
